|
BMI (<25kg/m2) |
BMI (25-29.9kg/m2) |
BMI (≥30kg/m2) |
|||||||||
|
Genes |
Methylated/ Unmethylated |
OR |
95% CI |
|
Methylated/ Unmethylated |
OR |
95% CI |
|
Methylated/ Unmethylated |
OR |
95% CI |
|
APC |
110/106 |
1.00 |
reference
|
90/89 |
0.97 |
(0.65,
1.45) |
76/71 |
1.03 |
(0.68,
1.57) |
||
|
BRCA1 |
127/102 |
1.00 |
reference
|
117/76 |
1.24 |
(0.84,
1.82) |
86/73 |
0.95 |
(0.63,
1.42) |
||
|
CDH1 |
16/193 |
1.00 |
reference
|
11/156 |
0.86 |
(0.39,
1.91) |
6/143 |
0.50 |
(0.19,
1.31) |
||
|
CYCLIND2 |
43/166 |
1.00 |
reference
|
40/127 |
1.20 |
(0.73,
1.97) |
33/116 |
1.15 |
(0.69,
1.93) |
||
|
DAPK |
29/180 |
1.00 |
reference
|
26/141 |
1.13 |
(0.64,
2.01) |
27/122 |
1.43 |
(0.81,
2.55) |
||
|
ESR1 |
106/122 |
1.00 |
reference
|
81/110 |
0.85 |
(0.58,
1.25) |
78/81 |
1.11 |
(0.74,
1.66) |
||
|
GSTP1 |
55/154 |
1.00 |
reference
|
46/121 |
1.06 |
(0.67,
1.67) |
42/107 |
1.12 |
(0.70,
1.79) |
||
|
HIN |
118/91 |
1.00 |
reference
|
112/55 |
1.57 |
(1.03,
2.39) |
97/52 |
1.44 |
(0.94,
2.23) |
||
|
CDKN2A |
7/202 |
1.00 |
reference
|
9/164 |
1.67 |
(0.61,
4.61) |
6/137 |
1.28 |
(0.42,
3.89) |
||
|
PR |
34/196 |
1.00 |
reference
|
21/172 |
0.70 |
(0.39,
1.25) |
15/144 |
0.60 |
(0.31,
1.14) |
||
|
RARB |
64/145 |
1.00 |
reference
|
49/118 |
0.93 |
(0.60,
1.46) |
37/112 |
0.76 |
(0.47,
1.23) |
||
|
RASSF1A |
176/33 |
1.00 |
reference
|
146/21 |
1.28 |
(0.71,
2.32) |
122/27 |
0.86 |
(0.49,
1.52) |
||
|
TWIST |
36/173 |
1.00 |
reference
|
|
30/137 |
1.05 |
(0.61,
1.79) |
|
22/127 |
0.84 |
(0.47,
1.51) |
Table
1: Age-adjusted
odds ratios (ORs) and 95% confidence intervals (CIs) for the association
between postmenopausal body mass index (BMI) and breast cancer, as defined by
gene-specific promoter methylation (comparing methylated vs. unmethylated
cases), Long Island Breast Cancer Study Project (1996-1997).